アクセス数 : ?
ダウンロード数 : ?
ID 112379
著者
Obara, Wataru Iwate Medical University
Kanehira, Mitsugu Iwate Medical University
Kato, Renpei Iwate Medical University
Kato, Yoichiro Iwate Medical University
Takata, Ryo Iwate Medical University
キーワード
cancer peptide vaccine therapy
oncoantigen
prostate cancer
renal cell carcinoma
urothelial cancer
資料タイプ
学術雑誌論文
抄録
Use of peptide-based vaccines as therapeutics aims to elicit immune responses through antigenic epitopes derived from tumor antigens. Peptide-based vaccines are easily synthesized and lack significant side-effects when given in vivo. Peptide-based vaccine therapy against several cancers including urological cancers has made progress for several decades, but there is no worldwide approved peptide vaccine. Peptide vaccines were also shown to induce a high frequency of immune response in patients accompanied by clinical efficacy. These data are discussed in light of the recent progression of immunotherapy caused by the addition of immune checkpoint inhibitors thus providing a general picture of the potential therapeutic efficacy of peptide-based vaccines and their combination with other biological agents. In this review, we discuss the mechanism of the antitumor effect of peptide-based vaccine therapy, development of our peptide vaccine, recent clinical trials using peptide vaccines for urological cancers, and perspectives of peptide-based vaccine therapy.
掲載誌名
Cancer Science
ISSN
13497006
出版者
Japanese Cancer Association
109
3
開始ページ
550
終了ページ
559
発行日
2018-01-18
権利情報
© 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
EDB ID
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
先端酵素学研究所